Esketamine nasal spray shows promise in treatment-resistant depression
In the realm of treatment-resistant depression, where conventional therapies often fall short, a recent study has shed light on a potential breakthrough. The research published in NEJM showed that esketamine nasal spray, combined with SSRIs or SNRIs, demonstrates superior efficacy in achieving remission in treatment-resistant depression compared to extended-release quetiapine augmentation therapy..
This phase 3b, randomized, active-controlled trial, conducted as an open-label, single-blind study with raters unaware of group assignments, sought to address the pressing need for effective treatments for patients who do not respond to multiple consecutive therapies during their current depressive episode.
A total of 676 patients were assigned to two groups in a 1:1 ratio, with one group receiving flexible doses of esketamine nasal spray and the other extended-release quetiapine. Both groups continued their ongoing treatment with an SSRI or SNRI.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.